569 related articles for article (PubMed ID: 10882875)
21. Prostate biopsy: who, how and when. An update.
Djavan B; Milani S; Remzi M
Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
[TBL] [Abstract][Full Text] [Related]
22. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
[TBL] [Abstract][Full Text] [Related]
23. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases.
Kang SH; Bae JH; Park HS; Yoon DK; Moon DG; Kim JJ; Cheon J
Int J Urol; 2006 Jul; 13(7):910-4. PubMed ID: 16882054
[TBL] [Abstract][Full Text] [Related]
25. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
26. Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml or less.
Noldus J; Stamey TA
J Urol; 1996 Feb; 155(2):441-3. PubMed ID: 8558630
[TBL] [Abstract][Full Text] [Related]
27. [Usefulness and predictive value of PSA density, adjusted by transition zone volume, in men with PSA levels between 2 and 4 ng/ml].
Janane A; Hajji F; Ismail T; Jawad C; Elondo JC; Dakka Y; Ghadouane M; Ameur A; Abbar M; Albouzidi A
Actas Urol Esp; 2012 Feb; 36(2):93-8. PubMed ID: 22188752
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
Krumholtz JS; Carvalhal GF; Ramos CG; Smith DS; Thorson P; Yan Y; Humphrey PA; Roehl KA; Catalona WJ
Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen adjusted for the transition zone volume versus free-to-total prostate-specific antigen ratio in predicting prostate cancer.
Moon DG; Cheon J; Kim JJ; Yoon DK; Koh SK
Int J Urol; 1999 Sep; 6(9):455-62. PubMed ID: 10510891
[TBL] [Abstract][Full Text] [Related]
30. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
[TBL] [Abstract][Full Text] [Related]
31. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
Postma R; de Vries SH; Roobol MJ; Wildhagen MF; Schröder FH; van der Kwast TH
Cancer; 2005 Feb; 103(4):708-16. PubMed ID: 15648082
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
33. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
[TBL] [Abstract][Full Text] [Related]
34. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
35. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study.
Reissigl A; Pointner J; Horninger W; Ennemoser O; Strasser H; Klocker H; Bartsch G
Urology; 1995 Nov; 46(5):662-5. PubMed ID: 7495117
[TBL] [Abstract][Full Text] [Related]
36. Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study.
Rietbergen JB; Kranse R; Hoedemaeker RF; Kruger AE; Bangma CH; Kirkels WJ; Schröder FH
Urology; 1998 Aug; 52(2):237-46. PubMed ID: 9697788
[TBL] [Abstract][Full Text] [Related]
37. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
Leewansangtong S; Tantiwong A; Ratanarapee S; Nualyong C; Soontrapa S
J Med Assoc Thai; 2000 Dec; 83(12):1519-24. PubMed ID: 11253893
[TBL] [Abstract][Full Text] [Related]
38. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
39. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
[TBL] [Abstract][Full Text] [Related]
40. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.
Aleman M; Karakiewicz PI; Kupelian P; Kattan MW; Graefen M; Cagiannos I; Eastham J; Scardino PT; Huland H; Klein EA
Urology; 2003 Jul; 62(1):70-4. PubMed ID: 12837425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
